Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for UroGen Pharma (URGN) over the last 8 years, with Q3 2025 value amounting to $3.3 million.

  • UroGen Pharma's Cost of Revenue rose 3363.23% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 3372.82%. This contributed to the annual value of $8.9 million for FY2024, which is 512.77% down from last year.
  • Latest data reveals that UroGen Pharma reported Cost of Revenue of $3.3 million as of Q3 2025, which was up 3363.23% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Cost of Revenue registered a high of $3.6 million during Q2 2025, and its lowest value of $897000.0 during Q1 2021.
  • For the 5-year period, UroGen Pharma's Cost of Revenue averaged around $2.1 million, with its median value being $2.3 million (2022).
  • In the last 5 years, UroGen Pharma's Cost of Revenue soared by 287291.67% in 2021 and then crashed by 2370.86% in 2024.
  • UroGen Pharma's Cost of Revenue (Quarter) stood at $1.6 million in 2021, then skyrocketed by 42.42% to $2.3 million in 2022, then grew by 1.02% to $2.3 million in 2023, then increased by 8.09% to $2.5 million in 2024, then soared by 32.66% to $3.3 million in 2025.
  • Its Cost of Revenue was $3.3 million in Q3 2025, compared to $3.6 million in Q2 2025 and $2.3 million in Q1 2025.